Great Point Partners LLC Sells 641,574 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Great Point Partners LLC reduced its position in Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) by 40.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 959,953 shares of the company's stock after selling 641,574 shares during the period. Voyager Therapeutics makes up 1.7% of Great Point Partners LLC's investment portfolio, making the stock its 21st largest holding. Great Point Partners LLC owned about 1.76% of Voyager Therapeutics worth $5,616,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. ProShare Advisors LLC purchased a new stake in Voyager Therapeutics in the 1st quarter valued at $101,000. Vanguard Group Inc. raised its position in Voyager Therapeutics by 27.8% in the 1st quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company's stock valued at $30,087,000 after buying an additional 702,030 shares during the last quarter. American International Group Inc. raised its position in Voyager Therapeutics by 22.9% in the 1st quarter. American International Group Inc. now owns 19,397 shares of the company's stock valued at $181,000 after buying an additional 3,610 shares during the last quarter. Lazard Asset Management LLC increased its position in shares of Voyager Therapeutics by 95.3% during the 1st quarter. Lazard Asset Management LLC now owns 18,742 shares of the company's stock valued at $174,000 after purchasing an additional 9,146 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Voyager Therapeutics by 3.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,041,930 shares of the company's stock valued at $9,702,000 after purchasing an additional 37,144 shares during the last quarter. 48.03% of the stock is currently owned by institutional investors.

Voyager Therapeutics Stock Down 1.4 %

Shares of NASDAQ VYGR opened at $5.67 on Wednesday. Voyager Therapeutics, Inc. has a 52 week low of $5.19 and a 52 week high of $11.72. The business has a 50-day simple moving average of $6.53 and a two-hundred day simple moving average of $7.36. The company has a market cap of $309.75 million, a P/E ratio of 7.99 and a beta of 0.89.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.29. The firm had revenue of $24.63 million during the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same quarter last year, the company posted ($0.59) EPS. Equities research analysts anticipate that Voyager Therapeutics, Inc. will post -1.03 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on VYGR. HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Voyager Therapeutics in a research report on Thursday, November 14th. StockNews.com raised Voyager Therapeutics from a "hold" rating to a "buy" rating in a research report on Monday, November 18th. Leerink Partners began coverage on Voyager Therapeutics in a research report on Wednesday, October 16th. They set an "outperform" rating and a $15.00 target price for the company. Leerink Partnrs upgraded Voyager Therapeutics to a "strong-buy" rating in a research note on Wednesday, October 16th. Finally, Wedbush cut their price target on Voyager Therapeutics from $8.00 to $7.00 and set a "neutral" rating for the company in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $17.00.

Insider Activity

In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the firm's stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total transaction of $34,914.18. Following the transaction, the insider now directly owns 86,001 shares of the company's stock, valued at approximately $500,525.82. This trade represents a 6.52 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 4.53% of the company's stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.

Want to see what other hedge funds are holding VYGR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.